NCT05533892 2023-12-19
CCGLC-007
Tongji Hospital
Phase 1 Unknown
Clinical Trials
6 trialsNCT05767684 2023-08-25
Neoantigen Derived DCs as Cancer Treatment
National Health Research Institutes, Taiwan
Phase 1 Unknown
NCT05675462 2023-03-06
Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma
Fudan University
Phase 1 Unknown
NCT05225116 2023-02-08
Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
Beijing Tsinghua Chang Gung Hospital
Phase 1 Unknown
NCT05221775 2022-02-03
Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Unknown
NCT05171530 2021-12-29
Lenvatinib With Taxane Drugs Treatment for Advanced Gastric Cancer
Ruijin Hospital
Phase 1 Unknown